Continued strong sales of its Definity ultrasound contrast agent and stable revenues from nuclear products powered growth for Lantheus Medical Imaging's parent company, Lantheus Holdings, in its second quarter (end-June 30).
Revenue increased 6% to $78 million, compared with $73.3 million in the second quarter of 2015. The company posted net income of $7.3 million, compared with a net loss of $24.4 million in last year's second quarter. Second-quarter net income reflected a decrease in the amount of interest expense due to debt refinancing in June of 2015.
For the six-month period, revenue advanced 4% to $154.4 million, compared with $148.1 million in the first half of 2015. Net income totaled $17.7 million, compared with a net loss of $24 million in the same period of 2015.
Lantheus Holdings also forecasted third-quarter worldwide revenue of $68 million to $70 million, as well as worldwide revenue of $291 million to $295 million for all of 2016.
